Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Psychiatry

Manuscript NO: 64875

Title: Recent Advances in the treatment of opioid use disorders – focus on long-acting buprenorphine formulations

Reviewer's code: 00505042
Position: Editorial Board
Academic degree: PhD
Professional title: Professor
Reviewer's Country/Territory: United States
Author's Country/Territory: Germany

Manuscript submission date: 2021-02-24
Reviewer chosen by: AI Technique
Reviewer accepted review: 2021-03-08 23:12
Reviewer performed review: 2021-03-09 00:10
Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ] Yes [Y] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous Conflicts-of-Interest: [ ] Yes [Y] No

Baishideng Publishing Group

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

The author presents a comprehensive review of buprenorphine and its slow-release formulations. References are up to date, and the relative advantages of these formulations are covered in detail. Thereby, the review will be useful to clinicians and patients as well. A few relatively minor issues need o be addressed. Page 5. 'The overall findings indicate a 1-year retention rate of 57% and a 3-year retention rate of 38.4%. A number of factors modify the retention rate: age, (additional) substance use, dose of the maintenance drug, legal issues and attitudes towards OMT predict outcome.' It would be helpful to provide a comparison between methadone and buprenorphine gleaned from this or other studies. page 7. '13.2% of OUD patients had injection-site adverse events' This is also the case fort the other formulations. It would be helpful to discuss whether this is a substantial issue, in view of the long duration of the treatment at the local site. Page 7. 'Usually, treatment with CAM 2038 is initiated with weekly injections. Later on the patient can be transferred from sublingual to monthly depot injections.' This does not make sense. Page 10. 'The FDA had require (spelling) a special risk management for this treatment. The „Probuphine Risk Evaluation and Mitigation Strategy" (REMS) program was initiated (https://probuphinerems.com). Meanwhile Titan Pharmaceuticals on oct 15, 2020 announced to discontinue its US propupine implant sales.' This requires further diuscussion; why did Titan discontinue the drug? Page 23>. Is morphine a full agonist? Typically it is viewed as partial agonist with relatively high efficacy. A number typos and phrases need correting: 'there is now doubt about the efficacy of these compounds'. Supposedly, 'no doubt' is meant. 'The adherence to treatment depends on adequate dosing and retention can be improved by adaquate dosage ' 'were given in patients with opioid dependent.'' With resepect to the injection sites mild local reactions were reported by 18.-22 % of the participants.'

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

'Overall these date indicate that RBP-6000 is effective.' 'The efficacy of buvidal has also studied demonstrated in several clinical trials.' 'he dose of the buprenorphine implant released' 'Steady state conditions were noted recorded after3-4 weeks ' 'In additions, the utilization of health care ressources will be reduced.' 'Depot formulations are alraedy used in prisons' 'will probably be no major problem introdocing'